Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 7/20 | 0.45 |
| ▸ | QPCTL | Q9NXS2 | 5/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | KDR | P35968 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | PRKCI | P41743 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4398362 | 0.82 | MAP3K11 (0.49) | LCKKDRJAK3MAPK14BRD4 | |
| SCHEMBL4398342 | 0.81 | FGFR1 (0.49) | KDRJAK3KMT2AKDM4EMAPT | |
| Ammonia Solution, Strong SCHEMBL6500596 | 0.80 | QPCT (0.46) | QPCTQPCTLLCKKDRJAK3 | |
| SCHEMBL4393565 | 0.80 | MAPKAPK2 (0.52) | QPCTQPCTLMAPK14KMT2AKDM4E | |
| SCHEMBL4399087 | 0.80 | LCK (0.45) | LCKKDRJAK3MAPK14KDM4E | |
| SCHEMBL4396796 | 0.80 | LCK (0.38) | LCKKDRJAK3MAPK14MAPT | |
| SCHEMBL4401602 | 0.78 | DYRK1A (0.44) | LCKKDRJAK3MAPK14PIK3CA | |
| SCHEMBL4400611 | 0.76 | TNIK (0.38) | LCKKDRJAK3MAPK14KMT2A | |
| SCHEMBL4399060 | 0.75 | ULK1 (0.46) | KMT2AKDM4EMAPTNPC1ALDH1A1 | |
| SCHEMBL4393571 | 0.74 | PIK3CA (0.51) | KMT2APIK3CAMTORTNIKDHFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514445-B2 | Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-07 | — | — | US | claimed |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | US | claimed |
| EP-1448556-A1 | HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-25 | — | — | EP | claimed |
| WO-2003037891-A1 | HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | claimed |
| US-20090306045-A1 | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-12-10 | — | — | US | disclosed |
| US-7514445-B2 | Heteroaryl amines as glycogen synthase kinase 3β inhibitors (GSK3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-07 | — | — | US | disclosed |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-01-06 | — | — | US | disclosed |
| EP-1448556-A1 | HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-08-25 | — | — | EP | disclosed |
| WO-2003037891-A1 | HETEROARYL AMINES AS GLYCOGEN SYNTHASE KINASE 3BETA INHIBITORS (GSK3 INHIBITORS) | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306045-A1 | Inhibition of Glycogen Synthase Kinase and Methods of Treating Autoimmune or Immune Inflammatory Disease | GSK3B, GSK3A, GSKIP | QPCT 2085/4885QPCTL 4447/4885LCK 146/4885 |
| US-20050004125-A1 | Heteroaryl amines as glycogen synthase kinase 3beta inhibitors (gsk3 inhibitors) | GSK3B, GSK3A, GSKIP | QPCT 882/4885QPCTL 2873/4885LCK 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.